Dayvigo (Lemborexant) Patent Expiration, LOE Window & CMS Spending

Dayvigo (Lemborexant) by Eisai: FDA Orange Book core substance LOE 2031-09-20 (last listed 2035-10-21), 0 AB generics, $26.4M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEisai
FDA Application & PathwayN212028 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-09-20
Last Listed Patent or Exclusivity Date2035-10-21
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$26.4M
2024 Medicare Part D Spend$21.0M
2024 Medicaid Spend$5.4M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 19.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.